Matthias, Christoph

[["dc.bibliographiccitation.firstpage","307"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","Oral and Maxillofacial Surgery"],["dc.bibliographiccitation.lastpage","309"],["dc.bibliographiccitation.volume","17"],["dc.contributor.author","Brandt, Andreas"],["dc.contributor.author","Schaefer, Inga-Marie"],["dc.contributor.author","Rustenbeck, Hans"],["dc.contributor.author","Matthias, Christoph"],["dc.contributor.author","Laskawi, Rainer"],["dc.date.accessioned","2019-07-09T11:39:48Z"],["dc.date.available","2019-07-09T11:39:48Z"],["dc.date.issued","2013"],["dc.description.abstract","Possible complications of parotid gland surgery are numerous, just as the reasons for aneurysms of the superficial temporal artery. The occurrence of such an aneurysm as a consequence of parotidectomy, however, has so far only been published once. Here, we report of an aneurysm of the superficial temporal artery following parotid gland surgery. It presented as a pulsating mass in the preauricular region. Combining clinical examination, duplex ultrasound, and CT scan, the diagnosis was readily established and treated with a circumscribed revision at low risk and without complications."],["dc.identifier.doi","10.1007/s10006-012-0385-y"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/10320"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/58039"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.publisher","Springer"],["dc.publisher.place","Berlin/Heidelberg"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Aneurysm of the superficial temporal artery following parotid gland surgery-Case report and review of the literature"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","267"],["dc.bibliographiccitation.journal","BMC Cancer"],["dc.bibliographiccitation.volume","8"],["dc.contributor.author","Matthias, Christoph"],["dc.contributor.author","Mack, Brigitte"],["dc.contributor.author","Berghaus, Alexander"],["dc.contributor.author","Gires, Olivier"],["dc.date.accessioned","2018-11-07T11:10:55Z"],["dc.date.available","2018-11-07T11:10:55Z"],["dc.date.issued","2008"],["dc.description.abstract","Background: The intermediate filament forming protein keratin 8 (K8) is a tumour-associated antigen, which was shown to be over-expressed in a variety of malignancies. Here, we present a study of K8 expression in squamous epithelia of the head and neck area, including normal mucosa, hyperplastic and dysplastic leukoplakia, carcinomas of different sub-localisations, and lymph node metastases. Methods: K8 expression was assessed upon immunohistochemistry with specific antibodies in cryosections of primary tumours of the head and neck area. Results: K8 expression was characteristic of transformed tissue and marked early stages of disease, i.e. dysplastic oral leukoplakia, but not normal or hyperplastic epithelium. With the exception of carcinomas of the larynx and the tongue, K8 expression also strictly differentiated carcinomas from normal epithelium of the same origin. Furthermore, K8(high) was characteristic of cells, which had detached from the sites of primary tumours and had been invading the surrounding tissue at the time point of surgery. Conclusion: K8 is an excellent marker for head and neck malignancies, which allows for early detection as well as for visualisation of potentially disseminating tumour cells in vivo."],["dc.description.sponsorship","Deutsche Forschungsgemeinschaft [G1-540/1-1]"],["dc.identifier.doi","10.1186/1471-2407-8-267"],["dc.identifier.isi","000259747300001"],["dc.identifier.pmid","18803884"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/4955"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/53312"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Biomed Central Ltd"],["dc.relation.issn","1471-2407"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Keratin 8 expression in head and neck epithelia"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","45"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","ORL-JOURNAL FOR OTO-RHINO-LARYNGOLOGY AND ITS RELATED SPECIALTIES"],["dc.bibliographiccitation.lastpage","49"],["dc.bibliographiccitation.volume","71"],["dc.contributor.author","Roedel, Ralf M. W."],["dc.contributor.author","Christiansen, Hans"],["dc.contributor.author","Mueller, Roland M."],["dc.contributor.author","Matthias, Christoph"],["dc.date.accessioned","2018-11-07T08:35:18Z"],["dc.date.available","2018-11-07T08:35:18Z"],["dc.date.issued","2009"],["dc.description.abstract","Background: To investigate long-term results of transoral CO 2 laser microresection (TLM) in glottic carcinoma in situ (CIS). Methods: A retrospective study of 34 patients with glottic CIS treated initially with TLM between 1986 and 2004. Median post-operative follow-up time was 62 months. Results: Three- and 5-year local control rates were 97 and 93%, respectively. Four patients developed local recurrence (rTis, rTis, rT1, rT4) that could be salvaged by repeated TLM in all cases. Neither adjuvant radiotherapy nor open partial or total laryngectomy was performed. There was no tumour-related death in this series. Conclusion: TLM can be considered as an effective method in the treatment of glottic CIS not only for the primary therapy, but also in cases of local recurrence. Copyright (c) 2008 S. Karger AG, Basel"],["dc.identifier.doi","10.1159/000176191"],["dc.identifier.isi","000261521900009"],["dc.identifier.pmid","19033717"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/9330"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/18030"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Karger"],["dc.relation.issn","0301-1569"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Transoral Laser Microsurgery for Carcinoma in situ of the Glottic Larynx"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","2719"],["dc.bibliographiccitation.issue","10"],["dc.bibliographiccitation.journal","European Archives of Oto-Rhino-Laryngology"],["dc.bibliographiccitation.lastpage","2727"],["dc.bibliographiccitation.volume","270"],["dc.contributor.author","Canis, Martin"],["dc.contributor.author","Ihler, Friedrich"],["dc.contributor.author","Martin, Alexios"],["dc.contributor.author","Wolff, Hendrik Andreas"],["dc.contributor.author","Matthias, Christoph"],["dc.contributor.author","Steiner, Wolfgang"],["dc.date.accessioned","2018-11-07T09:20:45Z"],["dc.date.available","2018-11-07T09:20:45Z"],["dc.date.issued","2013"],["dc.description.abstract","The main objective of this study is to assess the feasibility of transoral laser microsurgery (TLM) in the treatment of T4a laryngeal cancer and to report the oncological and functional outcomes. This is a retrospective case-series study, held in a single-institute, academic tertiary referral center. Seventy-nine patients with previously untreated T4a glottic (n = 31, 39 %) or supraglottic laryngeal carcinoma (n = 48, 61 %) were included in this study. Five patients (6 %) were treated exclusively by TLM, 16 (20 %) had TLM and unilateral neck dissection, 27 (35 %) had TLM and bilateral neck dissection. Adjuvant (chemo)radiotherapy was additionally administered in 26 (33 %) cases following TLM and neck dissection, and in 5 (6 %) cases after TLM without neck dissection. The main outcome measures included organ preservation, local control, functional outcome, overall, recurrence-free, and disease-specific survival. The median follow-up period was 49 months, 5 year organ preservation rate and local control rate were 80.0 and 67.2 %, 5 year overall, recurrence-free and disease-specific survival were 55.8, 61.9 and 71.8 %. The 5 year overall survival rates were 62.5 % in pN0 cases and 57.2 % in cases with pN-positive neck disease. With respect to survival, these results are comparable to total laryngectomy, while being superior to primary (chemo)radiotherapy. TLM results in a low morbidity, rapid recovery and good function and can be a valid option for organ preserving surgery of pT4a glottic and supraglottic cancer."],["dc.identifier.doi","10.1007/s00405-013-2382-7"],["dc.identifier.isi","000323739100020"],["dc.identifier.pmid","23408021"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/10308"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/28952"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.relation.issn","0937-4477"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Organ preservation in T4a laryngeal cancer: is transoral laser microsurgery an option?"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","145"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Radiation and Environmental Biophysics"],["dc.bibliographiccitation.lastpage","154"],["dc.bibliographiccitation.volume","50"],["dc.contributor.author","Wolff, Hendrik Andreas"],["dc.contributor.author","Rolke, David"],["dc.contributor.author","Rave-Fraenk, Margret"],["dc.contributor.author","Schirmer, Markus"],["dc.contributor.author","Eicheler, Wolfgang"],["dc.contributor.author","Doerfler, Annegret"],["dc.contributor.author","Hille, Andrea"],["dc.contributor.author","Hess, Clemens Friedrich"],["dc.contributor.author","Matthias, Christoph"],["dc.contributor.author","Roedel, Ralf M. W."],["dc.contributor.author","Christiansen, Hans"],["dc.date.accessioned","2018-11-07T08:58:47Z"],["dc.date.available","2018-11-07T08:58:47Z"],["dc.date.issued","2011"],["dc.description.abstract","The purpose of this work was to analyze chemokine and chemokine receptor expression in untreated and in irradiated squamous cell carcinoma of the head and neck (SCCHN) tumor cell lines, aiming at the establishment of assays to test for the relevance of chemokine and chemokine receptor expression in the response of SCCHN to radiotherapy and radiochemotherapy. Five low passage and 10 established SCCHN lines, as well as two normal cell lines, were irradiated at 2 Gy or sham-irradiated, and harvested between 1 and 48 h after treatment. For chemokines with CC and CXC structural motifs and their receptors, transcript levels of target and reference genes were quantified relatively by real-time PCR. In addition, CXCL1 and CXCL12 protein expression was analyzed by ELISA. A substantial variation in chemokine and chemokine receptor expression between SCCHN was detected. Practically, all cell lines expressed CCL5 and CCL20, while CCL2 was expressed in normal cells and in some of the tumor cell lines. CXCL1, CXCL2, CXCL3, CXCL10, and CXCL11 were expressed in the vast majority of the cell lines, while the expression of CXCL9 and CXCL12 was restricted to fibroblasts and few tumor cell lines. None of the analyzed cell lines expressed the chemokines CCL3, CCL4, or CCL19. Of the receptors, transcript expression of CCR1, CCR2, CCR3, CCR5, CCR7, CCXR2, and CCXR3 was not detected, and CCR6, CXCR1, and CXCR4 expression was restricted to few tumor cells. Radiation caused up- and down-regulation with respect to chemokine expressions, while for chemokine receptor expressions down-regulations were prevailing. CXCL1 and CXCL12 protein expression corresponded well with the mRNA expression. We conclude that the substantial variation in chemokine and chemokine receptor expression between SCCHN offer opportunities for the establishment of assays to test for the relevance of chemokine and chemokine receptor expression in the response of SCCHN to radiotherapy and radiochemotherapy."],["dc.identifier.doi","10.1007/s00411-010-0341-x"],["dc.identifier.isi","000287512400013"],["dc.identifier.pmid","21085979"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/6619"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/23728"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.relation.issn","0301-634X"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Analysis of chemokine and chemokine receptor expression in squamous cell carcinoma of the head and neck (SCCHN) cell lines"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","2315"],["dc.bibliographiccitation.issue","8"],["dc.bibliographiccitation.journal","European Archives of Oto-Rhino-Laryngology"],["dc.bibliographiccitation.lastpage","2326"],["dc.bibliographiccitation.volume","270"],["dc.contributor.author","Canis, Martin"],["dc.contributor.author","Martin, Alexios"],["dc.contributor.author","Ihler, Friedrich"],["dc.contributor.author","Wolff, Hendrik Andreas"],["dc.contributor.author","Kron, Martina"],["dc.contributor.author","Matthias, Christoph"],["dc.contributor.author","Steiner, Wolfgang"],["dc.date.accessioned","2018-11-07T09:22:08Z"],["dc.date.available","2018-11-07T09:22:08Z"],["dc.date.issued","2013"],["dc.description.abstract","The objective of the study was to evaluate the oncological and functional results of transoral laser microsurgery (TLM) in patients with supraglottic laryngeal squamous cell carcinoma. Between June 1980 and December 2006, 277 patients with squamous cell supraglottic carcinoma of all stages were treated by primary carbon dioxide laser microsurgery. All treatments were performed with curative intention. The goal was the complete tumor removal with preservation of functionally important structures of the larynx. The administered treatment was exclusively TLM with or without selective or modified radical neck dissection in 215 cases (78 %); TLM with postoperative radiotherapy was performed in 62 cases (22 %). Data were analyzed using the Kaplan-Meier method. The median follow-up was 65 months. We achieved a 5-year local control rate of 85 % for pT1/pT2, 82 % for pT3, and 76 % for pT4. The 5-year overall, recurrence-free and disease-specific survival rates for stages I and II were 76, 81, and 92 %, for stages III and IVa 59, 65, and 81 %, respectively. With respect to local control and survival, these results are comparable with the results achieved by conventional partial and total resection of the larynx, while being superior to primary (chemo)radiotherapy. Transoral laser microsurgery results in a low morbidity, rapid recovery, and superior function compared with standard therapy."],["dc.identifier.doi","10.1007/s00405-012-2327-6"],["dc.identifier.isi","000321286600020"],["dc.identifier.pmid","23306348"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/10307"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/29270"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.relation.issn","0937-4477"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Results of transoral laser microsurgery for supraglottic carcinoma in 277 patients"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","961"],["dc.bibliographiccitation.issue","7"],["dc.bibliographiccitation.journal","Journal of Cancer Research and Clinical Oncology"],["dc.bibliographiccitation.lastpage","967"],["dc.bibliographiccitation.volume","135"],["dc.contributor.author","Wolff, Hendrik Andreas"],["dc.contributor.author","Overbeck, Tobias R."],["dc.contributor.author","Roedel, Ralf M. W."],["dc.contributor.author","Hermann, Robert Michael"],["dc.contributor.author","Herrmann, Markus Karl Alfred"],["dc.contributor.author","Kertesz, Tereza"],["dc.contributor.author","Vorwerk, Hilke"],["dc.contributor.author","Hille, Andrea"],["dc.contributor.author","Matthias, Christoph"],["dc.contributor.author","Hess, Clemens Friedrich"],["dc.contributor.author","Christiansen, Hans"],["dc.date.accessioned","2018-11-07T08:28:13Z"],["dc.date.available","2018-11-07T08:28:13Z"],["dc.date.issued","2009"],["dc.description.abstract","To evaluate toxicity of radiochemotherapy schedule using daily-low-dose-cisplatin in radiochemotherapy of locally-advanced head-and-neck-cancer (HNSCC). From October 2003 to October 2006, 50 patients with HNSCC (stage III/IVA/IVB) were treated. In 32 patients, surgery and adjuvant radiotherapy(64 Gy), in 18 patients definitive radiotherapy(70 Gy) was performed. Low-dose-cisplatin was applied concomitantly (6 mg/m(2)/every radiotherapy-day). Acute toxicity a parts per thousand yengrade 3 was observed in 22 patients (11 patients mucositis/dysphagia, 7 hematologic toxicity, 4 mucositis/dysphagia/hematologic toxicity). 90% of our patients received > 80% of the planned cumulative chemotherapy dose, 94% the intended dose of radiotherapy. After median follow-up of 24.2 months, 3-year overall survival and loco-regional control rates were 67.1 and 78%. During follow-up, chronic toxicity a parts per thousand yengrade 3 (xerostomia, subcutaneous fibrosis, or lymphedema) was observed in nine patients. We found chemoradiation with daily-low-dose-cisplatin to be feasible with advantage of low acute and chronic toxicity. Therefore, use of low-dose-cisplatin should be evaluated in future clinical trials."],["dc.identifier.doi","10.1007/s00432-008-0532-x"],["dc.identifier.isi","000266477900012"],["dc.identifier.pmid","19107519"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?goescholar/3539"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/16373"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.relation.issn","1432-1335"],["dc.relation.issn","0171-5216"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Toxicity of daily low dose cisplatin in radiochemotherapy for locally advanced head and neck cancer"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","89"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Journal of Cancer Research and Clinical Oncology"],["dc.bibliographiccitation.lastpage","97"],["dc.bibliographiccitation.volume","136"],["dc.contributor.author","Wolff, Hendrik Andreas"],["dc.contributor.author","Roedel, Ralf M. W."],["dc.contributor.author","Gunawan, Bastian"],["dc.contributor.author","Overbeck, Tobias R."],["dc.contributor.author","Herrmann, Markus Karl Alfred"],["dc.contributor.author","Hennies, Steffen"],["dc.contributor.author","Hille, Andrea"],["dc.contributor.author","Vorwerk, Hilke"],["dc.contributor.author","Matthias, Christoph"],["dc.contributor.author","Hess, Clemens Friedrich"],["dc.contributor.author","Christiansen, Hans"],["dc.date.accessioned","2018-11-07T08:47:54Z"],["dc.date.available","2018-11-07T08:47:54Z"],["dc.date.issued","2010"],["dc.description.abstract","Nasopharyngeal carcinomas (NPC) are radiosensitive, and radiotherapy is the standard curative treatment. Furthermore, it has been shown that combined radiochemotherapy improves prognosis in locally advanced stages. Further encouraging results have been obtained with adjuvant interferon-beta after primary radio(chemo)therapy in childhood undifferentiated NPC. Aim of the present study was to evaluate the treatment results after long-term follow-up after radio(chemo)therapy for adult NPC with special reference to patients with undifferentiated carcinomas treated with adjuvant interferon-beta. From 02/1992 to 07/2008, 26 adult patients with NPC without distant metastases were treated (17 squamous cell carcinomas, 9 undifferentiated carcinomas). The treatment concepts changed over the years: 13 patients were treated with radiotherapy alone, 13 patients received combined radiochemotherapy. Additionally, six patients with undifferentiated carcinomas were treated with adjuvant interferon-beta after radiochemotherapy for 6 months. After a median follow-up of 96 months, 17 patients remain alive. Collectively, our 5-year overall-survival and loco-regional control rates were 74% (radiochemotherapy 81%, radiotherapy alone 68.5%) and 87% (radiochemotherapy 100%, radiotherapy alone 72.7%), respectively. All treatment regimens used were feasible; especially, adjuvant interferon-beta was applied as provided without high grade toxicity. All patients with undifferentiated carcinomas treated with adjuvant interferon-beta stayed alive until the end of the follow-up. In summary, our data affirm that NPC in adults are curable by primary radio(chemo)therapy. Furthermore, our data indicate that adjuvant interferon-beta application in undifferentiated NPC in adults is feasible and shows promising results. Further prospective clinical trials are needed to finally establish adjuvant interferon beta in curative treatment of adult NPC."],["dc.identifier.doi","10.1007/s00432-009-0640-2"],["dc.identifier.isi","000271981600011"],["dc.identifier.pmid","19618214"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?goescholar/4152"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/21075"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.relation.issn","0171-5216"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Nasopharyngeal carcinoma in adults: treatment results after long-term follow-up with special reference to adjuvant interferon-beta in undifferentiated carcinomas"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","2299"],["dc.bibliographiccitation.issue","8"],["dc.bibliographiccitation.journal","European Archives of Oto-Rhino-Laryngology"],["dc.bibliographiccitation.lastpage","2306"],["dc.bibliographiccitation.volume","270"],["dc.contributor.author","Canis, Martin"],["dc.contributor.author","Martin, Alexios"],["dc.contributor.author","Kron, Martina"],["dc.contributor.author","Konstantinou, Alexandra"],["dc.contributor.author","Ihler, Friedrich"],["dc.contributor.author","Wolff, Hendrik Andreas"],["dc.contributor.author","Matthias, Christoph"],["dc.contributor.author","Steiner, Wolfgang"],["dc.date.accessioned","2018-11-07T09:22:07Z"],["dc.date.available","2018-11-07T09:22:07Z"],["dc.date.issued","2013"],["dc.description.abstract","The objective of this study is to assess the feasibility of transoral laser microsurgery (TLM) in the treatment of squamous cell cancer of the tonsil and to report the oncological and functional outcomes, using retrospective chart review in the setting of single-institute, academic tertiary referral center. Between October 1987 and December 2006, 102 patients were eligible for this study, mostly suffering from advanced disease: 13 % presented with stage I and II (UICC/AJCC 2002) tumors and 87 % with stages III and IVa. The median follow-up was 63 months. All patients were treated by TLM with (or without) neck dissection (95 %) and with (66 %) postoperative radiotherapy. Overall survival, recurrence-free survival, disease-free survival, local control and loco-regional control were analyzed as end points. Rate of tracheotomies, postoperative complications and swallowing function were also analyzed. 5-year Kaplan-Meier local and loco-regional control was 78 % for pT1 and pT2 and 75 % for pT3 and pT4a tumors. 5-year Kaplan-Meier disease-free survival, recurrence-free survival, and overall survival and was 74, 64 and 59 % for stage I and II, 68, 60 and 56 % for stage III and IVa, respectively. Our data supports the conclusion, that TLM should be considered as a therapeutic option for the treatment of cancer of the tonsil. The oncological and functional results are comparable to any other treatment regimen, while the morbidity and complications tend to be lower."],["dc.identifier.doi","10.1007/s00405-012-2335-6"],["dc.identifier.isi","000321286600018"],["dc.identifier.pmid","23274878"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/10306"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/29267"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.relation.issn","0937-4477"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Results of transoral laser microsurgery in 102 patients with squamous cell carcinoma of the tonsil"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","281"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","Oral and Maxillofacial Surgery"],["dc.bibliographiccitation.lastpage","285"],["dc.bibliographiccitation.volume","17"],["dc.contributor.author","Laskawi, Rainer"],["dc.contributor.author","Winterhoff, Jan"],["dc.contributor.author","Köhler, Sabrina"],["dc.contributor.author","Kottwitz, Laura"],["dc.contributor.author","Matthias, Christoph"],["dc.date.accessioned","2019-07-09T11:39:49Z"],["dc.date.available","2019-07-09T11:39:49Z"],["dc.date.issued","2012"],["dc.description.abstract","Salivary fistulas are a well-known sequel of parotidectomy, and successful treatment with botulinum toxin has been demonstrated in individual cases. Here, we report on 12 patients with fistulas treated following parotidectomy for various indications.Injection of botulinum toxin type A into the residual gland tissue was the initial treatment. After early intervention (within 6 weeks after development of the fistula), only one fistula remained (9 of 10 fistulas treated early only with botulinum toxin). One patient with early intervention did not want to wait for the botulinum toxin treatment to take effect and demanded early surgical revision, which was successful. In one patient with a permanent fistula, botulinum toxin treatment began 420 days after the operation and was unsuccessful. No side effects were evident after the treatment.In summary, botulinum toxin injections into the parotid tissue remaining after surgery appear to be an effective treatment for salivary fistulas following parotidectomy."],["dc.identifier.doi","10.1007/s10006-012-0375-0"],["dc.identifier.fs","593833"],["dc.identifier.pmid","23179957"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/10323"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/58042"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.publisher","Springer"],["dc.publisher.place","Berlin/Heidelberg"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Botulinum toxin treatment of salivary fistulas following parotidectomy: follow-up results"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]